Harmony Biosciences is trading at $33.52, down 9.70% on November 4, 2026, after Q3 adjusted EPS of $0.81 fell short of the $1.00 consensus. - Revenue was $268.92 million, also below the cited estimate; WAKIX revenue grew year over year. - New royalty charges and milestone costs weighed on earnings. Full-year revenue guidance was reaffirmed, so the earnings miss—not a guidance cut—is the clearest explanation for the decline.